Supplementary Table 2. Association between hypertension and CSVD imaging markers in participants with low and high TBIL concentrations

CSVD imaging markers	Group	N	n (%)	Adj. OR/cOR (95% CI)*	*P*	*P* for interaction
WMH burden[†]	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	119 (9.3)	Ref.		0.047
	Hypertension	943	247 (26.2)	2.45 (1.76–3.40)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	57 (12.2)	Ref.		
	Hypertension	374	87 (23.3)	1.27 (0.74–2.17)	0.392	
Modified WMH burden[‡]	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276		Ref.		0.032
	Hypertension	943		2.04 (1.58–2.63)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468		Ref.		
	Hypertension	374		1.14 (0.75–1.74)	0.542	
Lacunes	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	32 (2.5)	Ref.		0.960
	Hypertension	943	80 (8.5)	2.27 (1.29–4.00)	0.005	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	16 (3.4)	Ref.		
	Hypertension	374	42 (11.2)	2.06 (0.91–4.64)	0.081	
Presence of CMBs[§]	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	95 (7.5)	Ref.		0.643
	Hypertension	943	119 (12.6)	1.16 (0.75–1.79)	0.506	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	44 (9.4)	Ref.		
	Hypertension	374	55 (14.7)	1.02 (0.55–1.92)	0.947	
CMB burden[‖]	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276		Ref.		0.730
	Hypertension	943		1.16 (0.75–1.79)	0.513	
	Participants with TBIL >17 μmol/L					
	No hypertension	468		Ref.		
	Hypertension	374		1.08 (0.58–2.01)	0.808	
BG-EPVS (moderate-to-severe)[¶]	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	72 (5.6)	Ref.		0.505
	Hypertension	943	127 (13.5)	1.42 (0.91–2.21)	0.123	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	39 (8.3)	Ref.		
	Hypertension	374	62 (16.6)	1.21 (0.63–2.30)	0.572	
BG-EPVS (severe)**	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	7 (0.6)	Ref.		0.811
	Hypertension	943	13 (1.4)		0.903	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	7 (1.5)	Ref.		
	Hypertension	374	11 (2.9)	0.56 (0.10–2.98)	0.495	

All models were adjusted for age, sex, body mass index, current smoking, current drinking, diabetes, dyslipidemia, antihypertensive medication, antiplatelet medication, anticoagulant medication, and alanine aminotransferase and aspartate aminotransferase levels.
CSVD, cerebral small vessel disease; TBIL, total bilirubin; Adj., adjust; OR, odds ratio; cOR, common odds ratio; CI, confidence interval; WMH, white matter hyperintensity; CMBs, cerebral microbleeds; BG-EPVS, basal ganglia enlarged perivascular space; Ref., reference.
*The associations of hypertension with WMH burden, lacune, presence of CMBs, and BG-EPVS were evaluated with OR, while with modified WMH burden and CMB burden were evaluated with cOR. The product term of hypertension state and TBIL group was included in the model to assess the effect modification by TBIL; [†]WMH burden was defined as either (early) confluent deep WMHs (Fazekas score 2 or 3) or irregular periventricular WMHs extending into the deep white matter (Fazekas score 3); [‡]Modified WMH burden was classified into grade 0 (total periventricular+subcortical WMHs score 1–2), grade 1 (total periventricular+subcortical WMHs score 3–4), and grade 2 (total periventricular+subcortical WMHs score 5–6); [§]Presence of CMBs was defined as presence of CMBs; [‖]CMB burden was classified as grade 0 (absent), grade 1 (1–4 microbleeds), and grade 2 (≥5 microbleeds); [¶]BG-EPVS (moderate-to-severe) indicated >10 perivascular space in basal ganglia; **BG-EPVS (severe) indicated >20 perivascular space in basal ganglia.

 https://doi.org/10.5853/jos.2025.01935